Tenpoint Therapeutics raises €63.0M Series A round
12 July 2023· London, United Kingdom· health, ophthalmology, biotech, cell_therapy, b2b, deep_hardware
The funding was used to launch the company and develop its regenerative medicine platform, which utilizes engineered cell-based therapeutics and in vivo reprogramming to replace specialized ocular cell types lost to degenerative conditions.
Investors
LeadF-Prime Capital
Also participating
Eight RoadsSofinnova PartnersBritish Patient CapitalUCL Technology FundQiming Venture Partners USA
About Tenpoint Therapeutics
Stage
Series B
Headquarters
London, United Kingdom
Founded
2020
Team Size
51–200
Sectors
healthophthalmologybiotechcell_therapyb2bdeep_hardware